CAS
INO icon

CTC Alternative Strategies’s Inovio Pharmaceuticals INO Stock Holding History

CTC Alternative Strategies’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,833
Closed -$9.82K – 127
2023
Q2 		$9.82K Buy
+1,833
New +$14.8K 0.01% 155
2014
Q2 		– Sell
-1,060
Closed -$169K – 236
2014
Q1 		$169K Buy
+1,060
New +$152K 0.1% 111

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

CTC Alternative Strategies's INO Position: Q3 2023 in Review

CTC Alternative Strategies sold out of Inovio Pharmaceuticals (INO) in Q3 2023, closing a stake of 1,833 shares — an estimated $9.82K sold.

CTC Alternative Strategies first reported a position in INO in Q1 2014 and held it in 2 quarters. The position peaked at $169K in Q1 2014. 124 funds tracked by Wall St. Rank hold INO as of Q3 2023.

  • CTC Alternative Strategies reported no remaining Inovio Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • CTC Alternative Strategies sold 1,833 Inovio Pharmaceuticals shares in Q3 2023, an estimated $9.82K.
  • CTC Alternative Strategies first reported a position in Inovio Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • CTC Alternative Strategies's Inovio Pharmaceuticals position peaked at $169K in Q1 2014.
  • 124 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2023.

Based on CTC Alternative Strategies's 13F filing for Q3 2023, filed 31 Oct 2023.